Skip to main content

Table 4 Reduction in prevalence of carriage with the MVC-4 vaccine

From: The impact of aggregating serogroups in dynamic models of Neisseria meningitidis transmission

Vaccine Program 

Model Type

Serogroup

t = 149

t = 160

t = 175

t = 190

Relative Change

4

4-strain model

B

0.031

0.031

0.035

0.036

0.202

 

(0.014)

(0.013)

(0.013)

(0.010)

(0.259)

C

0.015

0.011

0.001

0.000

−0.958

 

(0.013)

(0.009)

(0.001)

(0.000)

(0.198)

Other

0.045

0.037

0.011

0.001

−0.974

 

(0.026)

(0.022)

(0.010)

(0.003)

(0.052)

Nl

0.025

0.024

0.023

0.022

−0.118

 

(0.003)

(0.002)

(0.002)

(0.003)

(0.080)

Total

0.117

0.102

0.070

0.059

−0.492

 

(0.056)

(0.047)

(0.027)

(0.017)

(0.060)

5

4-strain model

B

0.030

0.032

0.035

0.035

0.206

 

(0.014)

(0.015)

(0.016)

(0.017)

(0.275)

C

0.013

0.006

0.000

0.000

−0.920

 

(0.015)

(0.008)

(0.002)

(0.000)

(0.271)

Other

0.046

0.031

0.008

0.000

−0.971

 

(0.028)

(0.020)

(0.009)

(0.001)

(0.139)

Nl

0.026

0.024

0.023

0.023

−0.106

 

(0.007)

(0.003)

(0.002)

(0.005)

(0.135)

Total

0.115

0.093

0.067

0.059

−0.487

 

(0.064)

(0.046)

(0.029)

(0.023)

(0.087)

6

4-strain model

B

0.029

0.031

0.033

0.034

0.244

 

(0.019)

(0.017)

(0.019)

(0.020)

(0.352)

C

0.016

0.017

0.000

0.000

−0.960

 

(0.019)

(0.009)

(0.000)

(0.000)

(0.196)

Other

0.043

0.021

0.003

0.000

−0.957

 

(0.034)

(0.017)

(0.005)

(0.000)

(0.196)

Nl

0.025

0.024

0.022

0.022

−0.121

 

(0.004)

(0.002)

(0.003)

(0.002)

(0.066)

Total

0.113

0.082

0.059

0.057

−0.499

 

(0.075)

(0.045)

(0.028)

(0.023)

(0.090)

  1. Reduction in the prevalence of carriage when an immunization program with the quadrivalent MCV-4 vaccine is scheduled for 12 month (program 4), 12 year (program 5), and 12 months and 12 years (program 9) beginning at t = 150 years. Results for the 4-strain model are shown